Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

269
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
269
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The PIECES multi-site comparative case study protocol: mixed methods implementation evaluation of adapting, implementing and tailoring primary cancer prevention programmes in diverse contexts.

Implementation science communications·2026
Same author

Vegetarian Diet and the Mechanics of Root Canal Dentin: Surface Hardness, Scanning Electron Microscopy-quantified Tubule Irregularity, and Diametral Tensile Strength.

Journal of endodontics·2026
Same author

Maximising the public health benefits of smokefree prisons: a synopsis from a mixed-methods study.

Public health research (Southampton, England)·2026
Same author

Impact of later trading hours for bars and clubs on alcohol-related ambulance call-outs and crimes in Scotland: a controlled interrupted time series study.

BMJ public health·2026
Same author

Twenty years on from smoke-free legislation in Scotland: A secondary analysis of the Scottish Health Survey dataset (1998-2024) examining changes in household smoking rules, and salivary cotinine concentrations among non-smokers.

Tobacco induced diseases·2026
Same author

How are bars and nightclubs in Scotland using extensions in late-night alcohol trading hours? Venue observation study.

The International journal on drug policy·2026

Related Experiment Video

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Drug Development.

Salvatore Napoli1, Rachel O'Donnell1, Lauren Nassr1

  • 1Alzheimer's Neurology and Infusion Centers of New England, Foxborough, MA, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
PubMed
Summary

Lecanemab treatment in early Alzheimer's disease (AD) showed improved cognitive scores and a favorable safety profile consistent with clinical trials. Real-world data suggest lecanemab is well-tolerated and effective in slowing AD progression.

More Related Videos

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

Related Experiment Videos

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Lecanemab, a monoclonal antibody, targets amyloid-beta (Aβ) protofibrils and plaques.
  • It has demonstrated efficacy in slowing clinical decline in early Alzheimer's disease (AD).

Purpose of the Study:

  • To present real-world clinical experience with lecanemab in early AD patients.
  • To evaluate the safety and tolerability of lecanemab in a clinical setting.

Main Methods:

  • Retrospective case series of 35 early AD patients treated with lecanemab.
  • Data included demographics, clinical history, treatment exposure, MMSE, MoCA, and safety assessments.
  • Clinician perspectives and patient survey feedback were collected.

Main Results:

  • Improved mean MMSE and MoCA scores at 6 and 12 months.
  • Favorable safety profile with manageable adverse events like ARIA and infusion-site reactions.
  • 80% patient satisfaction reported, with perceived stabilization or slowing of disease progression.

Conclusions:

  • Real-world evidence supports lecanemab's safety and tolerability in early AD.
  • Findings align with clinical trials demonstrating lecanemab's ability to slow disease progression.
  • Further longitudinal studies are needed to assess long-term outcomes.